Kenvue Stock (KVUE) Under Scrutiny as Trump Administration Links Tylenol to Autism Risk

Kenvue (KVUE), the consumer health spin-off of Johnson & Johnson, faces potential market turbulence as the TRUMP administration prepares to announce a suspected link between Tylenol's active ingredient and autism risk during pregnancy. The Washington Post reports federal health officials may advise against early-pregnancy use of the pain reliever, while promoting leucovorin as a potential autism treatment.

The impending announcement—described by Trump as "one of the most important things" his administration will do—could trigger regulatory actions, litigation, or consumer backlash against Kenvue's flagship product. Tylenol accounted for significant revenue under JNJ before the 2023 spinoff.

Market analysts anticipate volatility in KVUE shares as investors weigh the potential financial impact of altered usage guidelines and legal exposure. The development highlights growing scrutiny of pharmaceutical products' neurodevelopmental effects.